Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Surrozen Inc. Warrant (SRZNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: SRZNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -50% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.57 | 52 Weeks Range 0.01 - 0.09 | Updated Date 05/20/2025 |
52 Weeks Range 0.01 - 0.09 | Updated Date 05/20/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.7 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -971.62% |
Management Effectiveness
Return on Assets (TTM) -21.41% | Return on Equity (TTM) -456.32% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 5400593 |
Shares Outstanding - | Shares Floating 5400593 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Surrozen Inc. Warrant
Company Overview
History and Background
Surrozen, Inc. was a biopharmaceutical company focused on discovering and developing novel regenerative medicines. The warrants likely arose from a special purpose acquisition company (SPAC) merger.
Core Business Areas
- Regenerative Medicine Development: Focused on therapies to regenerate tissue to restore organ function. Their focus was on Wnt signaling.
Leadership and Structure
Details on leadership and organizational structure are not readily available for the warrant itself, as it is tied to the parent company's structure, which has likely changed since the company's dissolution.
Top Products and Market Share
Key Offerings
- SZN-1326: A Wnt mimetic for severe alcoholic hepatitis. Clinical trials were underway. Competitors are those pursuing treatments for liver diseases.
- SZN-043: A Wnt mimetic for inflammatory bowel disease. Pre-clinical development. Competitors are those pursuing treatments for IBD.
Market Dynamics
Industry Overview
The regenerative medicine industry aims to repair or replace damaged tissues and organs. It is a high-growth area with significant unmet medical needs.
Positioning
Surrozen aimed to be a leader in Wnt-mediated regenerative therapies, but they are no longer actively pursuing this market.
Total Addressable Market (TAM)
The TAM for regenerative medicine is estimated to be in the tens of billions of dollars. Surrozen aimed to capture a share of this market with their Wnt-based therapies, but they are no longer positioned to do so.
Upturn SWOT Analysis
Strengths
Weaknesses
- Financial instability that lead to dissolution
Opportunities
Threats
Competitors and Market Share
Key Competitors
Competitive Landscape
Not applicable due to Surrozen ceasing operations.
Growth Trajectory and Initiatives
Historical Growth: There is no growth to report.
Future Projections: No future projections are available as Surrozen is not operational.
Recent Initiatives: N/A
Summary
Surrozen Inc. ceased operations and the warrant is likely worthless. The company's focus was on regenerative medicine using Wnt signaling pathways, but they were unable to sustain operations. Any perceived value of the warrant is pure speculation. The company did not reach the milestone to be considered successful.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Market analysis reports
Disclaimers:
This analysis is based on publicly available information and the understanding that Surrozen has ceased operations. The warrant is likely to have very little to no value.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Surrozen Inc. Warrant
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2021-08-12 | CEO, President & Director Mr. Craig C. Parker M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 40 | Website https://www.surrozen.com |
Full time employees 40 | Website https://www.surrozen.com | ||
Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6 for the treatment of DME/wet AMD/uveitic macular edema; SZN-113 to treat Fuchs' endothelial corneal dystrophy and geographic atrophy; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of pulmonary fibrosis. Surrozen, Inc. is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.